Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Publication Date: 2018-06-29
    Description: Myotonic dystrophy type 2 (DM2) is a neuromuscular disease caused by an expansion of intronic CCTG repeats in the CNBP gene, which encodes a protein regulating translation and transcription. To better understand the role of cellular nucleic acid binding protein (CNBP) in DM2 pathology, we examined skeletal muscle in a new model of Cnbp knockout (KO) mice. This study showed that a loss of Cnbp disturbs myofibrillar sarcomeric organization at birth. Surviving homozygous Cnbp KO mice develop muscle atrophy at a young age. The skeletal muscle phenotype in heterozygous Cnbp KO mice was milder, but they developed severe muscle wasting at an advanced age. Several proteins that control global translation and muscle contraction are altered in muscle of Cnbp KO mice. A search for CNBP binding proteins showed that CNBP interacts with the α subunit of the dystroglycan complex, a core component of the multimeric dystrophin-glycoprotein complex, which regulates membrane stability. Whereas CNBP is reduced in cytoplasm of DM2 human fibers, it is a predominantly membrane protein in DM2 fibers, and its interaction with α-dystroglycan is increased in DM2. These findings suggest that alterations of CNBP in DM2 might cause muscle atrophy via CNBP-mediated translation and via protein-protein interactions affecting myofiber membrane function.
    Print ISSN: 0270-7306
    Electronic ISSN: 1098-5549
    Topics: Biology , Medicine
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010; 20100921-20100925; Mannheim; DOCP1727 /20100916/
    Publication Date: 2010-09-17
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Abstract: In den letzten Jahren hat sich der Workshop "Bildverarbeitung für die Medizin" durch erfolgreiche Veranstaltungen etabliert. Ziel ist auch 2010 wieder die Darstellung aktueller Forschungsergebnisse und die Vertiefung der Gespräche zwischen Wissenschaftlern, Industrie und Anwendern. Die Beiträge dieses Bandes - einige in englischer Sprache - behandeln alle Bereiche der medizinischen Bildverarbeitung, insbesondere Bildgebung, CAD, Segmentierung, Bildanalyse, Visualisierung und Animation, Roboter und Manipulatoren, Chirurgische Simulatoren, Diagnose, Therapieplanung sowie deren klinische Anwendungen.
    Type of Publication: Book chapter
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
  • 5
    Publication Date: 2008-12-10
    Description: The prevalence of fibromyalgia syndrome (FMS) of 1-2% in the general population associated with high disease-related costs and the conflicting data on treatment effectiveness had led to the development of evidence-based guidelines designed to provide patients and physicians guidance in selecting among the alternatives. Until now no evidence-based interdisciplinary (including patients) guideline for the management of FMS was available in Europe. Therefore a guideline for the management of fibromyalgia syndrome (FMS) was developed by 13 German medical and psychological associations and two patient self-help organisations. The task was coordinated by two German scientific umbrella organisations, the Association of the Scientific Medical Societies in Germany AWMF and the German Interdisciplinary Association of Pain Therapy DIVS. A systematic search of the literature including all controlled studies, systematic reviews and meta-analyses of pharmacological and non-pharmacological treatments of FMS was performed in the Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) and Scopus (1980-12/ 2006). Levels of evidence were assigned according to the classification system of the Oxford-Centre for Evidence Based Medicine. Grading of the strengths of recommendations was done according to the German program for disease management guidelines. Standardized procedures were used to reach a consensus on recommendations. The guideline was reviewed and finally approved by the boards of the societies involved and published online by the AWMF on april 25, 2008: http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm. A short version of the guideline for patients is available as well: http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm. The following procedures in the management of FMS were strongly recommended: information on diagnosis and therapeutic options and patient-centered communication, aerobic exercise, cognitive and operant behavioural therapy, multicomponent treatment and amitriptyline. Based on expert opinion, a stepwise FMS-management was proposed. Step 1 comprises confirming the diagnosis and patient education and treatment of physical or mental comorbidities or aerobic exercise or cognitive behavioural therapy or amitriptyline. Step 2 includes multicomponent treatment. Step 3 comprises no further treatment or self-management (aerobic exercise, stress management) and/or booster multicomponent therapy and/or pharmacological therapy (duloxetine or fluoxetine or paroxetine or pregabalin or tramadol/aminoacetophen) and/or psychotherapy (hypnotherapy or written emotional disclosure) and/or physical therapy (balneotherapy or whole body heat therapy) and/or complementary therapies (homoeopathy or vegetarian diet). The choice of treatment options should be based on informed decision-making and respect of the patients' preferences.
    Description: Die Prävalenz des Fibromyalgiesyndroms (FMS) in der allgemeinen Bevölkerung beträgt 1-2%. Aufgrund der mit FMS verbundenen hohen Krankheitskosten und den widersprüchlichen Daten zur Wirksamkeit einzelner Behandlungsformen wurden evidenzbasierte Leitlinien entwickelt, um Ärzten und Patienten einen Entscheidungshilfe zu geben. Bisher war in Europa keine interdisziplinäre evidenzbasierte Leitlinie unter Einschluss von Patienten zum FMS verfügbar. Deswegen wurde von 13 deutschen medizinischen und psychologischen Fachgesellschaften und zwei Patientenselbsthilfeorganisationen eine Leitlinie zu Therapie des FMS entwickelt. Die Durchführung wurde von der Deutschen Interdisziplinären Vereinigung für Schmerztherapie DIVS und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften in Deutschland AWMF koordiniert. Eine systematische Literatursuche aller kontrollierte Studien, systematischer Reviews und Metaanalysen wurde über die Datenbanken Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) und Scopus (1980-12/ 2006) durchgeführt. Für die Vergabe von Evidenzklassen wurde das System des Oxford-Centre for Evidence Based Medicine verwendet. Für die Vergabe von Empfehlungsgraden wurde die Empfehlungsgraduierung der nationalen Versorgungsleitlinien verwendet. Die Erstellung der Empfehlungen erfolgte in einem mehrstufigen nominalen Gruppenprozess, welcher von einer Vertreterin der AWMF moderiert wurde. Die Leitlinie wurde von den Vorständen der beteiligten Fachgesellschaften begutachtet und genehmigt. Die wissenschaftliche Lang- und Kurzversion der Leitlinie wurde am 25. April 2008 von der AWMF ins Internet gestellt: http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm. Eine Kurzversion für Patienten ist ebenfalls verfügbar: http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm. Folgende Therapieverfahren erhielten eine starke Empfehlung: Informationen über Diagnose und Behandlungsmöglichkeiten, patienten-zentrierte Kommunikation, aerobes Ausdauertraining, kognitive und operante Verhaltenstherapie, multimodale Therapie und Amitriptylin. Basierend auf Expertenmeinung wurde eine stufenweise Behandlung des FMS empfohlen: Stufe 1 beinhaltet Diagnosebestätigung und Patientenschulung und/oder Behandlung körperlicher und psychischer Komorbiditäten oder aerobes Ausdauertraining oder kognitive und operante Verhaltenstherapie oder Amitriptylin. Stufe 2 beinhaltet multimodale Therapie. Stufe 3 umfasst die folgenden Behandlungsoptionen: keine weitere Behandlung oder Selbstmanagement (aerobes Ausdauertraining, Stressmanagement) und/oder multimodale Auffrischungstherapie und/oder phamakologische Therapie (Duloxetin oder Fluoxetin oder Pregabalin oder Tramadol/Paracetamol) und/oder psychotherapeutische Verfahren (Hypnotherapie oder therapeutisches Schreiben) oder physikalische Therapie (Balneotherapie oder Ganzkörperwärmetherapie) und/oder komplementäre Therapien (Homöopathie oder vegetarische Kost). Die Wahl der Behandlungsoptionen soll auf gemeinsame Entscheidungsfindung und unter Berücksichtigung der Patientenpräferenzen durchgeführt werden.
    Keywords: FIBROMYALGIA/* ; FIBROMYALGIA/drug therapy ; FIBROMYALGIA/epidemiology ; FIBROMYALGIA/ therapy ; FIBROMYALGIA/* rehabilitation ; FIBROMYALGIA/ psychology ; PRACTICE GUIDELINES AS TOPIC ; EVIDENCE-BASED MEDICINE ; PATIENT EDUCATION AS TOPIC ; DELIVERY OF HEALTH CARE ; EUROPE ; PATIENT CARE TEAM ; QUALITY ASSURANCE, HEALTH CARE ; HUMANS ; FIBROMYALGIE/* ; FIBROMYALGIE/Arzneimitteltherapie ; FIBROMYALGIE/Epidemiologie ; FIBROMYALGIE ; FIBROMYALGIE/* ; FIBROMYALGIE ; KLINISCHE LEITLINIEN ; GUTACHTENBASIERTE MEDIZIN ; PATIENTENSCHULUNG ; GESUNDHEITSVERSORGUNG ; EUROPA ; KRANKENBEHANDLUNGSTEAM ; QUALITÄTSSICHERUNG IM GESUNDHEITSWESEN ; MENSCH ; fibromyalgia syndrome ; systematic review ; guideline ; management ; Fibromyalgiesyndrom ; systematische Übersicht ; Leitlinie ; Behandlung ; ddc: 610
    Language: English
    Type: article
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  InVeST 2015: International Veterinary Simulation in Teaching Conference; 20150914-20150916; Hannover; DOC15invest10 /20150910/
    Publication Date: 2015-09-11
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20150607-20150610; Karlsruhe; DOCDI.09.07 /20150602/
    Publication Date: 2015-06-03
    Keywords: meningioma ; supraorbital approach ; adverse events ; ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20130526-20130529; Düsseldorf; DOCDI.11.05 /20130521/
    Publication Date: 2013-05-22
    Keywords: subarachnoid hemorrhage ; DCI ; vasospams ; ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN); 20120912-20120915; Erlangen; DOC12dgnnPP2.1 /20120911/
    Publication Date: 2012-09-12
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: RECEPTOR ; CELLS ; EXPRESSION ; IN-VITRO ; SURVIVAL ; ENDOTHELIAL GROWTH-FACTOR ; Germany ; IN-VIVO ; MODEL ; MODELS ; PATHWAY ; PATHWAYS ; VITRO ; GENERATION ; VOLUME ; DEATH ; DISEASE ; DISEASES ; DRUG ; DIFFERENTIATION ; LIGAND ; MECHANISM ; RAT ; CELL-SURVIVAL ; CELL-DEATH ; LONG-TERM SURVIVAL ; TRANSIENT GLOBAL-ISCHEMIA ; STEM-CELLS ; CENTRAL-NERVOUS-SYSTEM ; COLONY-STIMULATING FACTOR ; STROKE ; signaling ; ADULT ; FOCAL CEREBRAL-ISCHEMIA ; NEURONS ; cell survival ; CEREBRAL-ISCHEMIA ; NEURAL STEM-CELLS ; cell death ; progenitor ; FUNCTIONAL RECOVERY ; MATURE ; RECOVERY ; NEURONAL DIFFERENTIATION ; HIPPOCAMPAL-NEURONS ; FACTOR G-CSF ; INFARCT ; NEWLY GENERATED NEURONS ; RAT DENTATE GYRUS
    Abstract: G-CSF is a potent hematopoietic factor that enhances survival and drives differentiation of myeloid lineage cells, resulting in the generation of neutrophilic granulocytes. Here, we show that G-CSF passes the intact blood-brain barrier and reduces infarct volume in 2 different rat models of acute stroke. G-CSF displays strong antiapoptotic activity in mature neurons and activates multiple cell survival pathways. Both G-CSF and its receptor are widely expressed by neurons in the CNS, and their expression is induced by ischemia, which suggests an autocrine protective signaling mechanism. Surprisingly, the G-CSF receptor was also expressed by adult neural stem cells, and G-CSF induced neuronal differentiation in vitro. G-CSF markedly improved long-term behavioral outcome after cortical ischemia, while stimulating neural progenitor response in vivo, providing a link to functional recovery. Thus, G-CSF is an endogenous ligand in the CNS that has a dual activity beneficial both in counteracting acute neuronal degeneration and contributing to long-term plasticity after cerebral ischemia. We therefore propose G-CSF as a potential new drug for stroke and neurodegenerative diseases
    Type of Publication: Journal article published
    PubMed ID: 16007267
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...